Huntington disease, a hereditary neurodegenerative disorder, leads to severe cognitive and motor impairments. Recent research from Florida Atlantic University has pinpointed the cGAS-STING immune pathway as a critical driver of inflammation in this disease. By genetically removing cGAS from humanized mouse models, researchers observed significant improvements in motor skills and reduced brain inflammation, indicating that blocking this pathway could slow disease progression. Further, treatment with the STING inhibitor H-151 yielded similar positive results. These findings suggest that targeting the cGAS-STING pathway might offer a more effective and scalable treatment option for Huntington disease, contrasting with current therapies that focus on reducing the huntingtin protein. Researchers believe that this approach could also be relevant for other neurodegenerative diseases, paving the way for new therapeutic strategies. The study highlights the potential for small-molecule drugs to provide accessible treatments for complex neurological conditions, with ongoing development of oral cGAS-STING inhibitors expected to facilitate future clinical applications.